Selected Tag: Cipla
Selected Tag: Cipla

Market Wrap

Benchmarks Post Weekly Losses as Oil Surge and IT Selloff Hit Sentiment

An end-of-day recap of all that transpired in the Indian markets, highlighting the major price movements and the factors driving them

Dehuti Jani

April 24, 2026 at 11:39 AM IST

Article related image

Market Wrap

Equities Extend Decline as Oil Surge and Strait Blockade Weigh on Sentiment

An end-of-day recap of all that transpired in the Indian markets, highlighting the major price movements and the factors driving them

Dehuti Jani

April 23, 2026 at 11:32 AM IST

Article related image

Amey Bane/iStockphoto.com

Market Wrap

Benchmarks Rise as Trump's Iran War Exit Lowers Oil Prices

An end-of-day recap of all that transpired in the Indian markets, highlighting the major price movements and the factors driving them

Dehuti Jani

April 1, 2026 at 11:15 AM IST

Article related image

istock

USFDA Classifies Cipla Partner Pharmathen's Greek Facility as Official Action Indicated

BasisPoint Insight

February 27, 2026 at 12:17 PM IST

Cipla October-December Net Profit Falls 57% to ₹6.76 Billion on gRevlimid Dip; India Revenue Grows 10%

BasisPoint Insight

January 27, 2026 at 9:41 AM IST

Market Wrap

Equities Slide as Rupee Hits Record Low Amid Foreign Outflows

An end-of-day recap of all that transpired in the Indian markets, highlighting the major price movements and the factors driving them

Dehuti Jani

January 23, 2026 at 11:41 AM IST

Article related image

Market Wrap

Equities Slip for Third Straight Session Amid Geopolitical Jitters

An end-of-day recap of all that transpired in the Indian markets, highlighting the major price movements and the factors driving them

Dehuti Jani

January 7, 2026 at 11:36 AM IST

Article related image

Amey Bane/iStockphoto.com

Cipla to Acquire Paediatric-focused Inzpera Healthsciences for ₹1.11 billion

BasisPoint Insight

November 4, 2025 at 6:53 AM IST

Cipla July-September Profit Rises 4% on Weak US Sales, Margins Under Pressure

BasisPoint Insight

October 31, 2025 at 6:31 AM IST

Most Indian Pharma Exports May Escape US Tariff, But Uncertainty Clouds Branded Generics 

US 100% tariff plan sparks confusion: if branded generics are treated as patented drugs, India is safe; if as branded imports, then some pharma exports face trouble.

Ajay Srivastava

September 26, 2025 at 7:56 AM IST

Article related image

Istock.com/moussa81

US FDA Issues OAI Status For Cipla’s Pithampur Plant

BasisPoint Insight

August 6, 2025 at 6:00 AM IST

Cipla April-June Profit Rises 10%, Revenue Growth At 21-Quarter Low

BasisPoint Insight

July 28, 2025 at 6:26 AM IST

Cipla To Buy 20% Stake In Medical Device Firm iCaltech For ₹50 Million

BasisPoint Insight

July 24, 2025 at 8:16 AM IST

Cipla Gets One Form 483 Observation For Bengaluru Unit

BasisPoint Insight

June 2, 2025 at 12:09 PM IST

Cipla To Pick Up 26% Stake In Solar SPV For ₹14.6 Million

BasisPoint Insight

May 21, 2025 at 9:58 AM IST

FDA Tags Cipla Arm Sitec Labs’ Navi Mumbai Unit As ‘Voluntary Action Indicated’

BasisPoint Insight

May 19, 2025 at 10:24 AM IST

Trump's "Most Favored Nation" Plan Exposes Indian Big Pharma's Concentration Risk

New executive order targeting drug prices reveals dangerous US dependency and accelerates the need for market diversification and higher-value products.

Dev Chandrasekhar

May 13, 2025 at 8:26 AM IST

Article related image

Cipla’s Goa Unit Gets ‘Voluntary Action Indicated’ From USFDA

BasisPoint Insight

April 22, 2025 at 8:32 AM IST

The Bureau

Deficient Monsoon, Iran War: A Double Shock to India’s Rural Economy
Learning to Shoot: I Tried to Fly Before I Could Walk
Image